



## Teligent Provides Update on Orphan Drug Complete Response Letter

April 22, 2019

BUENA, N.J., April 22, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced that on April 16, 2019, its development partner has filed the response to the Complete Response Letter ("CRL") it received on August 30<sup>th</sup>, 2018, regarding its pending ANDA for its orphan drug target.

"With the filing of this response we are one step closer to bringing this important, life-saving drug to patients," commented Jason Grenfell-Gardner, President and CEO of Teligent.

"We continue to be committed to bringing high-quality, lower-cost alternative products to patients," Mr. Grenfell-Gardner continued, "We have forty topical generic pharmaceutical products in the US portfolio, in addition to our four US injectable products."

### About Teligent, Inc.

Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website [www.teligent.com](http://www.teligent.com).

### Contact:

Damian Finio  
Teligent, Inc.  
856-336-9117  
[www.teligent.com](http://www.teligent.com)

### Forward-Looking Statements

This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as "plan," "believe," "continue," "should" or words of similar meaning. Factors that could cause actual results to differ materially from these expectations include, but are not limited to: our inability to meet current or future regulatory requirements in connection with existing or future ANDAs; our inability to achieve profitability; our failure to obtain FDA approvals as anticipated; our inability to execute and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect our intellectual property rights; changes in global political, economic, business, competitive, market and regulatory factors; and our inability to complete successfully future product acquisitions. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors" in Teligent, Inc.'s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other periodic reports we file with the Securities and Exchange Commission. Teligent, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.



Source: Teligent, Inc.